In advanced NSCLC, peripheral blood biomarkers including the tumor marker carcinoembryonic antigen (CEA) and the neutrophil over lymphocyte ratio (NLR) have been proposed as prognostic biomarkers useful for treatment monitoring (62). Here, CEACAM5 is linked to non-small cell lung carcinoma.